Khasraw, M., Lipton, L., Hofman, M., Gebski, V., Gill, A., Markman, B., … Chantrill, L. (2017). Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (Vol. 13, pp. 166–167). WILEY.

Khasraw, Mustafa, Lara Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, et al. “Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas.” In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13:166–67. WILEY, 2017.

Khasraw M, Lipton L, Hofman M, Gebski V, Gill A, Markman B, et al. Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas. In: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY; 2017. p. 166–7.

Khasraw, Mustafa, et al. “Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas.” ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 13, WILEY, 2017, pp. 166–67.

Khasraw M, Lipton L, Hofman M, Gebski V, Gill A, Markman B, Yip S, Gibbs E, Karapetis C, Pavlakis N, Wong SF, Ransom D, Sjoquist K, Michael M, Rayani U, Simes J, Chantrill L. Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY; 2017. p. 166–167.